

Works Cited

- Bergqvist, C., & Ezzedine, K. (2020). Vitiligo: A Review. *Dermatology*, 236(6), 1–22.
<https://doi.org/10.1159/000506103>
- Cai, Y., Chen, R., Gao, S., Li, W., Liu, Y., Su, G., Song, M., Jiang, M., Jiang, C., & Zhang, X. (2023). Artificial intelligence applied in neoantigen identification facilitates personalized cancer immunotherapy. *Frontiers in Oncology*, 12.
<https://doi.org/10.3389/fonc.2022.1054231>
- Cui, J., Arita, Y., & Bystrn, J. C. (1995). Characterization of Vitiligo Antigens. *Pigment Cell Research*, 8(1), 53–59. <https://doi.org/10.1111/j.1600-0749.1995.tb00774.x>
- Faraj, S., Kemp, E. H., & Gawkrödger, D. J. (2021). Patho-immunological mechanisms of vitiligo: the role of the innate and adaptive immunities and environmental stress factors. *Clinical and Experimental Immunology*, 207(1), 27–43.
<https://doi.org/10.1093/cei/uxab002>
- Ghashghaei, S., Abbaszadeh, M., Karimi, S., Ataie-Fashtami, L., Bajouri, A., & Vosough, M. (2023). Advanced Therapy Medicinal Products in Vitiligo; Current Status, Future Prospect, and Approved Treatments. *Cell Journal*, 25(3), 143–157.
<https://doi.org/10.22074/cellj.2023.557550.1067>
- Javaid, M., Haleem, A., Ravi P. S., Suman, R., & Rab, S. (2022). Significance of machine learning in healthcare: Features, pillars and applications. *International Journal of Intelligent Networks*, 3, 58–73. <https://doi.org/10.1016/j.ijin.2022.05.002>
- Lee, M., Shin, J.I., Yang, J.W., Lee, K.H., Cha, D., Hong, J.B., Park, Y., Choi, E., Tizaoui, K., Koyanagi, A., Jacob, L., Park, S., Kim, J., & Smith, L. (2022). Genome Editing Using CRISPR-Cas9 and Autoimmune Diseases: A Comprehensive Review. *International Journal of Molecular Sciences*, 23(3), 1337. <https://doi.org/10.3390/ijms23031337>
- Lu, Y.-C., & Robbins, P. F. (2015). Cancer immunotherapy targeting neoantigens. *Seminars in Immunology*, 28(1), 22–27. <https://doi.org/10.1016/j.smim.2015.11.002>
- Mosenson, J. A., Zloza, A., Nieland, J. D., Garrett-Mayer, E., Eby, J. M., Huelsmann, E. J., Kumar, P., Denman, C. J., Lacey, A. T., Kohlhapp, F. J., Alamiri, A., Hughes, T., Bines, S. D., Kaufman, H. L., Overbeck, A., Mehrotra, S., Hernandez, C., Nishimura, M. I., Guevara-Patino, J. A., & Le, C. (2013). Mutant HSP70 Reverses Autoimmune Depigmentation in Vitiligo. *Science Translational Medicine*, 5(174).
<https://doi.org/10.1126/scitranslmed.3005127>
- Passeron, T., Harris, J. E., Pandya, A. G., Seneschal, J., Grimes, P., Kornacki, D., Wang, M., Ezzedine, K., & Rosmarin, D. (2024). Repigmentation by body region in patients with

vitiligo treated with ruxolitinib cream over 52 weeks. *Journal of the European Academy of Dermatology and Venereology*. <https://doi.org/10.1111/jdv.20236>

- Perez-Bootello, J., Cova-Martin, R., Naharro-Rodriguez, J., & Segurado-Miravalles, G. (2023). Vitiligo: Pathogenesis and New and Emerging Treatments. *International Journal of Molecular Sciences*, 24(24), 17306–17306. <https://doi.org/10.3390/ijms242417306>
- Schmidt, C. (2020). Temprian Therapeutics: developing a gene-based treatment for vitiligo. *Nature*. <https://doi.org/10.1038/d41586-020-01808-5>
- Tang, Q., Gross, K. Y., Fakih, H. H., Jackson, S. O., Zain, M., Monopoli, K. R., Blanchard, C., Bouix-Peter, C., Portal, T., Harris, J. E., Khvorova, A., & Alterman, J. F. (2024). Multispecies-targeting siRNAs for the modulation of JAK1 in the skin. *Molecular Therapy — Nucleic Acids*, 35(1), 102117. <https://doi.org/10.1016/j.omtn.2024.102117>
- Tian, J., Olcott, A., Hanssen, L., Zekzer, D., & Kaufman, D. L. (1999). Antigen-based immunotherapy for autoimmune disease: from animal models to humans? *Immunology Today*, 20(4), 190–195. [https://doi.org/10.1016/s0167-5699\(99\)01445-0](https://doi.org/10.1016/s0167-5699(99)01445-0)